Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month (M) 12 of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa enteral suspension [CLES], in the US) treatment.
Background: Sleep disturbances occur in over 90% of PD patients and have a major impact on patient QoL and daytime function, particularly in the advanced stages of the disease. Although LCIG has been shown to improve both sleep disturbances and QoL in PD, there is limited data on the correlation between QoL and changes in sleep with LCIG infusion therapy.
Method: DUOGLOBE is an ongoing, prospective, multinational, observational study of LCIG naïve patients in a routine care setting (NCT02611713). In this post-hoc analysis of patients with available sleep-related outcomes data (N=172), Pearson correlations evaluated the relationship between QoL and sleep disturbances 1) at baseline (BL, prior to LCIG initiation) and 2) the absolute change from BL at M12 of LCIG treatment. Sleep disturbances were assessed by the Non-Motor Symptoms Scale (NMSS) sleep domain, Epworth Sleepiness Scale (ESS), and PD Sleep Scale (PDSS-2); QoL was assessed by the 8-item PD Questionnaire (PDQ-8). Serious adverse events were monitored in the safety population (N=196) for the entire patient follow-up.
Results: Prior to LCIG, QoL positively correlated with all sleep assessments (both physician- and patient-reported) including the NMSS sleep domain (r=0.400; P<.001), ESS (r=0.264; P<.001), and PDSS-2 (r=0.503; P<.001)[Table 1]. LCIG treatment significantly improved QoL and all sleep assessments at M12 [Table 2]. The absolute changes in QoL at M12 positively correlated with score improvements on the NMSS sleep domain (r=0.368; P<.001), ESS (r=0.401; P<.001), and PDSS-2 (r=0.538; P<.001) [Table 1]. Overall, 41% (n=80) of patients experienced SAEs and 31% (n=60) discontinued participation.
Conclusion: This post-hoc analysis further supports the relationship between sleep disturbances and QoL in advanced PD patients (prior to LCIG) and that the improved patient QoL after 12 months of LCIG therapy correlates with the beneficial effects of LCIG on sleep disturbances. The observed safety events were consistent with the established LCIG safety profile.
To cite this abstract in AMA style:
K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred. Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/positive-correlations-between-quality-of-life-and-sleep-dysfunction-in-advanced-parkinsons-disease-patients-prior-to-and-after-12-months-of-levodopa-carbidopa-intestinal-gel-treatment-an-ana/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/positive-correlations-between-quality-of-life-and-sleep-dysfunction-in-advanced-parkinsons-disease-patients-prior-to-and-after-12-months-of-levodopa-carbidopa-intestinal-gel-treatment-an-ana/